Clinical Trial Update: Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial of an anti-IL-5 monoclonal antibody for prednisone-dependent eosinophilic asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Eosinophilic Bronchitis

Drugs mentioned

• Anti-IL-5 monoclonal antibody

Snippet

Sponsor: McMaster University | Conditions: Severe Persistent Asthma, Eosinophilic Bronchitis | Phase 2, Phase 3 | Status: COMPLETED